Polymorphisms in the ace and ADRB2 genes and risks of aging-associated phenotypes: The case of myocardial infarction

Rejuvenation Research

Volumn 13, Issue 1, 2010, Pages 13-21

  Kulminski, Alexander M ^a   Culminskaya, Irina V ^a   Ukraintseva, Svetlana V ^a   Arbeev, Konstantin G ^a   Akushevich, Igor ^a   Land, Kenneth C ^a   Yashin, Anatoli I ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; AGING; ARTICLE; CASE REPORT; GENE DELETION; GENE INSERTION; HEART INFARCTION; HEART PROTECTION; HETEROZYGOSITY; HUMAN; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDEL MUTATION; LINKAGE DISEQUILIBRIUM; MALE; MASSACHUSETTS; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDYL-DIPEPTIDASE A; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADRENERGIC, BETA-2;

EID: 77949536886     PISSN: 15491684     EISSN: None     Source Type: Journal    
DOI: 10.1089/rej.2009.0905     Document Type: Article

References (39)

1. Olshansky SJ, Perry D, Miller RA, Butler RN. Pursuing the longevity dividend: Scientific goals for an aging world. Ann NY Acad Sci 2007;1114:11-13.
2. Franco OH, Karnik K, Osborne G, Ordovas JM, Catt M, van der Ouderaa F. Changing course in ageing research: The healthy ageing phenotype. Maturitas 2009;63:13-19.
3. Di Rienzo A, Hudson RR. An evolutionary framework for common diseases: The ancestral-susceptibility model. Trends Genet 2005;21:596-601.
4. Lanfear DE, Marsh S, Cresci S, Spertus JA, McLeod HL. Frequency of compound genotypes associated with beta-blocker efficacy in congestive heart failure. Pharmacoge-nomics 2004;5:553-558.
5. Crisan D, Carr J. Angiotensin I-converting enzyme: Genotype and disease associations. J Mol Diagn 2000;2:105-115.
6. Hindorff LA, Heckbert SR, Psaty BM, Lumley T, Siscovick DS, Herrington DM, Edwards KL, Tracy RP. Beta(2)-adrenergic receptor polymorphisms and determinants of cardiovascular risk: The cardiovascular health study. Am J Hypertens 2005;18:392-397.
7. Heckbert SR, Hindorff LA, Edwards KL, Psaty BM, Lumley T, Siscovick DS, Tang Z, Durda JP, Kronmal RA, Tracy RP. Beta2-adrenergic receptor polymorphisms and risk of incident cardiovascular events in the elderly. Circulation 2003; 107:2021-2024.
8. Sala G, Di Castelnuovo A, Cuomo L, Gattone M, Giannuzzi P, Iacoviello L, De Blasi A. The e27 beta2-adrenergic receptor polymorphism reduces the risk of myocardial infarction in dyslipidemic young males. Thromb Haemost 2001;85: 231-233. 9
9. Schurks M, Kurth T, Ridker PM, Buring JE, Zee RY. Association between polymorphisms in the beta2-adrenergic receptor gene with myocardial infarction and ischaemic stroke in women. Thromb Haemost 2009;101:351-358.
10. Herrmann SM, Nicaud V, Tiret L, Evans A, Kee F, Ruidavets JB, Arveiler D, Luc G, Morrison C, Hoehe MR, Paul M, Cambien F. Polymorphisms of the beta2-adrenoceptor (ADRB2) gene and essential hypertension: The ectim and pegase studies. J Hypertens 2002;20:229-235.
11. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion=deletion polymorphism in the an-giotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-1346.
12. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin i-converting enzyme (ACE) gene controls plasma ace levels. Am J Hum Genet 1992;51:197-205.
13. Zintzaras E, Raman G, Kitsios G, Lau J. Angiotensin-converting enzyme insertion=deletion gene polymorphic variant as a marker of coronary artery disease: A meta-analysis. Arch Intern Med 2008;168:1077-1089.
14. Agerholm-Larsen B, Nordestgaard BG, Tybjaerg-Hansen A. ACE gene polymorphism in cardiovascular disease: Meta-analyses of small and large studies in whites. Arterioscler Thromb Vasc Biol 2000;20:484-492.
15. Keavney B, McKenzie C, Parish S, Palmer A, Clark S, Youngman L, Delepine M, Lathrop M, Peto R, Collins R. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion=deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) collaborators. Lancet 2000;355:434-442.
16. Katzov H, Bennet AM, Kehoe P, Wiman B, Gatz M, Blennow K, Lenhard B, Pedersen NL, de Faire U, Prince JA. A cladistic model of ace sequence variation with implications for myocardial infarction, alzheimer disease and obesity. Hum Mol Genet 2004;13:2647-2657.
17. Pan M, Jiang MH, Wei MF, Liu ZH, Jiang WP, Geng HH, Cui ZC, Zhang DL, Zhu JH. Association of angiotensin-converting enzyme gene 2350 g a polymorphism with myocardial infarction in a chinese population. Clin Appl Thromb Hemost 2008;0: 1076029608316013v1.
18. Rana BK, Insel PA, Payne SH, Abel K, Beutler E, Ziegler MG, Schork NJ, O'Connor DT. Population-based sample reveals gene-gender interactions in blood pressure in white americans. Hypertension 2007;49:96-106.
19. Wetmore JB, Johansen KL, Sen S, Hung AM, Lovett DH. An angiotensin converting enzyme haplotype predicts survival in patients with end stage renal disease. Hum Genet 2006;120:201-210.
20. Zhu X, Bouzekri N, Southam L, Cooper RS, Adeyemo A, McKenzie CA, Luke A, Chen G, Elston RC, Ward R. Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ace concentration and blood pressure. Am J Hum Genet 2001;68:1139-1148.
21. McKenzie CA, Abecasis GR, Keavney B, Forrester T, Ratcliffe PJ, Julier C, Connell JM, Bennett F, McFarlane-Anderson N, Lathrop GM, Cardon LR. Trans-ethnic fine mapping of a quantitative trait locus for circulating angiotensin i-converting enzyme (ACE). Hum Mol Genet 2001;10:1077-1084.
22. Hadjadj S, Tarnow L, Forsblom C, Kazeem G, Marre M, Groop PH, Parving HH, Cambien F, Tregouet DA, Gut IG, Theva A, Gauguier D, Farrall M, Cox R, Matsuda F, Lathrop M, Hager-Vionnet N. Association between angiotensin-converting enzyme gene polymorphisms and diabetic ne-phropathy: Case-control, haplotype, and family-based study in three european populations. J Am Soc Nephrol 2007;18: 1284-1291.
23. Montecucco F, Mach F. Statins, ace inhibitors and arbs in cardiovascular disease. Best Pract Res Clin Endocrinol Metab 2009;23:389-400.
24. Brodde OE. Beta-1 and beta-2 adrenoceptor polymorphisms: Functional importance, impact on cardiovascular diseases and drug responses. Pharmacol Ther 2008;117:1-29.
25. Dupree CS. Primary prevention of heart failure: What is the evidence? Curr Opin Cardiol 2009;24:142-147.
26. Kitsios G, Zintzaras E. ACE (I=D) polymorphism and response to treatment in coronary artery disease: A comprehensive database and meta-analysis involving study quality evaluation. BMC Med Genet 2009;10:50.
27. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Cas-telli WP. An investigation of coronary heart disease in families. The Framingham Offspring Study. Am J Epidemiol 1979;110:281-290.
28. Govindaraju DR, Cupples LA, Kannel WB, O'Donnell CJ, Atwood LD, D'Agostino RB Sr, Fox CS, Larson M, Levy D, Murabito J, Vasan RS, Splansky GL, Wolf PA, Benjamin EJ. Genetics of the Framingham Heart Study population. Adv Genet 2008;62:33-65.
29. Dawber TR. The Framingham Study: The epidemiology of atherosclerotic disease. Harvard University Press, Cambridge, MA, 1980.
30. Gail MH, Johnson NL. Proceedings of the American Statistical Association: Sesquicentennial invited papers session. American Statistical Association, Alexandria, VA, 1989.
31. Cupples LA, Arruda HT, Benjamin EJ, D'Agostino RB, Sr., Demissie S, DeStefano AL, Dupuis J, Falls KM, Fox CS, Gottlieb DJ, Govindaraju DR, Guo CY, Heard-Costa NL, Hwang SJ, Kathiresan S, Kiel DP, Laramie JM, Larson MG, Levy D, Liu CY, Lunetta KL, Mailman MD, Manning AK, Meigs JB, Murabito JM, Newton-Cheh C, O'Connor GT, O'Donnell CJ, Pandey M, Seshadri S, Vasan RS, Wang ZY, Wilk JB, Wolf PA, Yang Q, Atwood LD. The Framingham Heart Study 100k SNP genome-wide association study resource: Overview of 17 phenotype working group reports. BMC Med Genet 2007;8(Suppl 1):S1.
32. Levy D, DePalma SR, Benjamin EJ, O'Donnell CJ, Parise H, Hirschhorn JN, Vasan RS, Izumo S, Larson MG. Phenotype-genotype association grid: A convenient method for summarizing multiple association analyses. BMC Genet 2006; 7:30.
33. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265.
34. Pettersson FH, Anderson CA, Clarke GM, Barrett JC, Cardon LR, Morris AP, Zondervan KT. Marker selection for genetic case-control association studies. Nat Protoc 2009; 4:743-752.
35. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA 2005;293:1861-1867.
36. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004;74:765-769.
37. Torkamani A, Topol EJ, Schork NJ. Pathway analysis of seven common diseases assessed by genome-wide association. Genomics 2008;92:265-272.
38. Phillips PC. Epistasis-the essential role of gene interactions in the structure and evolution of genetic systems. Nat Rev Genet 2008;9:855-867.
39. Kitsios GD, Zintzaras E: Genomic convergence of genome-wide investigations for complex traits. Ann Hum Genet 2009;73:514-519.